Redcare Pharmacy reported Q1 2026 German prescription revenue of €168 million, a 55% YoY increase and beating the €162 million consensus estimate.
Group revenue rose 18.3% to €848 million, surpassing analysts’ €837 million forecast, while non‑prescription sales grew 10% to €533 million.
Shares jumped over 14% to €40.96, near a 52‑week low of €30.20, with Jefferies maintaining a €150 price target and “buy” rating.
Active customers reached 14.2 million (+8% YoY) and e‑Rx satisfaction rose to 76 from 73, supporting the company’s 2026 guidance.